15709-74-7Relevant articles and documents
Heteroleptic copper(i) halides with triphenylphosphine and acetylthiourea: Synthesis, characterization and biological studies (experimental and molecular docking)
Khan, Syed Ishtiaq,Ahmad, Sajjad,Altaf, Ataf Ali,Rauf, Muhammad Khawar,Badshah, Amin,Azam, Syed Sikander,Tahir, Muhammad Nawaz
, p. 19318 - 19330 (2019)
Nine new copper complexes with the general formula [CuX(TPP)n(ATU)3-n] (where X = Cl, Br, and I, ATU = acetylthiourea, TPP = triphenylphosphine and n varies as 0, 1 and 2) were synthesized in a simple fashion, by changing the ratio of the ligands. The synthesized complexes were characterized by techniques, such as FT-IR and NMR spectroscopy, CHNS elemental analysis and single crystal X-ray technique. The XRD technique showed the monodentate behavior of TPP and ATU. The synthesized compounds were utilized in different biological assays, which showed anti-bacterial, anti-fungal, anti-lieshmanial, anti-oxidant and cytotoxic properties against brine shrimps. In parallel, molecular docking was carried out to decipher the binding conformation and chemical interactions of the compounds in the active binding pockets of biological drug targets against bacterial pathogens and lieshmanial parasite, as well as a cancer target. All these analyses revealed compounds [CuCl(TPP)(ATU)2] and [CuI(TPP)(ATU)2] to be the most effective molecules of the series. Molecular docking indicated that hydrogen bonding and hydrophobic pi-interactions play important role for the activities of complexes with ligands TPP/ATU ratio of 1/2.
Mononuclear copper(i) complexes of triphenylphosphine and: N, N ′-disubstituted thioureas as potential DNA binding chemotherapeutics
Khan, Syed Ishtiaq,Ahmad, Sajjad,Khan, Inayat Ali,Badshah, Amin,Rauf, Muhammad Khawar,Putejo, Jahangir Ali,Siddiq, Muhammad Nasir,Kausar, Samia,Altaf, Ataf Ali
, p. 8925 - 8935 (2021)
In this work, nine new mixed-ligand complexes with the general formula [CuBr(TPP)2Tu1-9] were synthesized. The copper(i) complexes of triphenylphosphine (TPP) and different N,N′-disubstituted thioureas (Tu) were characterized via spectroscopic techniques including Fourier transform infrared spectroscopy (FTIR), nuclear magnetic resonance spectroscopy (1H, 13C, and 31P NMR), and single-crystal X-ray diffraction (SC-XRD). The complexes were synthesized via the direct reaction of bromo(tris(triphenylphosphine)copper(i)) [BrCu(PPh3)3] precursor and thiourea ligand solution under ambient conditions. Complexes 1, 2 and 3 crystallized in a triclinic system with the P1 space group. Each complex is mononuclear, and the copper atom is tetrahedrally attached to two TPP groups through the phosphorous atom, one thiourea molecule through the sulfur atom and one bromine atom. The synthesized compounds were docked with a DNA macromolecule to predict their binding site and it was found that all molecules showed favorable binding to the DNA minor grooves. The DNA interaction studies of the representative complexes demonstrated their efficient DNA binding affinities. Based on the docking and DNA interaction results, complex 7 was found to be the best binder with a docking affinity of 382.2 kJ mol-1 and binding constant of 3.96 × 104 M-1. This compound tends to interact with the minor groove through the bromine atom positioning the side triphenylphosphine rings along the X-axis of the groove while keeping the 1-(2-chlorobenzyl)-3-(3-(trifluoromethyl)phenyl)thiourea ring on the outside.
Synthesis, structures, DNA-binding and anticancer activities of some copper(I)-phosphine complexes
Mashat, Khlood H.,Babgi, Bandar A.,Hussien, Mostafa A.,Nadeem Arshad, Muhammad,Abdellattif, Magda H.
, p. 164 - 172 (2019)
Copper(I) complexes with a phenanthroline-phosphine set of ligands were synthesized by refluxing methanolic solutions of CuBr2 with at least a four fold molar excess of the phosphine ligands, followed by the treatment of the formed {CuBr(PR3)3 complexes [R = phenyl (1a), 4-fluorophenyl (1b), cyclohexyl (1c) or 4-methoxyphenyl (1d)]} with 1 molar equivalent of 1,10-phenanthroline in DCM. The tris(4-methoxyphenyl)phosphine ligand afforded the complex [Cu(P[C6H4-4-OMe]3)2(phen)]Br (2d), while the other phosphines produced complexes with the general formula CuBr(PR3)(phen) [R = phenyl (2a), 4-fluorophenyl (2b) or cyclohexyl (2c)]. The new complexes were characterized by elemental analysis, 31P NMR spectroscopy and mass spectrometry. Additional confirmation of the structures of 1b, 2b, 2c and 2d were determined by single crystal X-ray diffraction. A DNA-binding study of the complexes 2a–2d against ct-DNA showed binding constant values that correspond to the intercalation mode of binding. The notable variations in the binding constants of the complexes suggest some contribution from the phosphine ligands. The lipophilicity of the complexes was evaluated theoretically and the calculated log P value of complex 2d is positive and high, being in the same range of relatively easy membrane penetrating drugs. The calculated log P values of complexes 2a–2c are negative, indicating a low membrane permeability. Complexes 2a–2d were examined against four different cancer cell lines. The choice of the phosphine ligand appears to influence the copper(I)-phosphine anticancer activities against the different cancer cell lines. The data suggested that complexes 2a and 2d show potential anticancer activity against prostate and breast cancers. The four copper complexes were docked against four different proteins associated with prostate or breast cancers activities, highlighting some of the structural-DNA interactions.
Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
-
Page/Page column 33, (2020/02/20)
The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
